Article Abstract

Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists—what will REWIND add?

Authors: Keith C. Ferdinand, Indrajeet Mahata


Type 2 diabetes mellitus (T2DM) is a complex metabolic disease with hyperglycemia and an associated high risk of cardiovascular disease (CVD), including macrovascular and microvascular complications. In addition, CVD mortality rates appear two fold higher among individuals with diabetes mellitus (DM) when compared to individuals without DM (1,2).